4.7 Review

Alpha/Beta-Hydrolase Domain-Containing 6: Signaling and Function in the Central Nervous System

Journal

FRONTIERS IN PHARMACOLOGY
Volume 12, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.784202

Keywords

ABHD6; endocannabinoid system; CPT1C; AMPA receptor; neurological diseases

Funding

  1. National Natural Science Foundation of China [81871023, 82171458, 81771322, 82171363, 82171321]
  2. Youth Nova Program of Shaanxi [2021KJXX-19]

Ask authors/readers for more resources

ABHD6 is a transmembrane serine hydrolase that plays important roles in neurotransmission, inflammation, and other biological processes. It has potential therapeutic implications for neurological diseases.
Endocannabinoid (eCB) signaling plays an important role in the central nervous system (CNS). alpha/beta-Hydrolase domain-containing 6 (ABHD6) is a transmembrane serine hydrolase that hydrolyzes monoacylglycerol (MAG) lipids such as endocannabinoid 2-arachidonoyl glycerol (2-AG). ABHD6 participates in neurotransmission, inflammation, brain energy metabolism, tumorigenesis and other biological processes and is a potential therapeutic target for various neurological diseases, such as traumatic brain injury (TBI), multiple sclerosis (MS), epilepsy, mental illness, and pain. This review summarizes the molecular mechanisms of action and biological functions of ABHD6, particularly its mechanism of action in the pathogenesis of neurological diseases, and provides a theoretical basis for new pharmacological interventions via targeting of ABHD6.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available